Have a personal or library account? Click to login
Unlocking the future of breast cancer biomarkers: A bibliometric perspective Cover

Unlocking the future of breast cancer biomarkers: A bibliometric perspective

By: Gamze Demirel  
Open Access
|Nov 2025

References

  1. Salim M, Liu Y, Sorkhei M, et al. AI-based selection of individuals for supplemental MRI in population-based breast cancer screening: the randomized ScreenTrustMRI trial. Nat Med. 2024; 30(9), 2623-2630. DOI: 10.1038/s41591-024-03093-5
  2. Kalia M. Biomarkers for personalized oncology: Recent advances and future challenges. Metabolism. 2015;64(3):S16-21. DOI: 10.1016/j.metabol.2014.10.027
  3. Tarighati E, Keivan H, Mahani H. A review of prognostic and predictive biomarkers in breast cancer. Clini experimental med. 2022; 23(1):1-16. DOI: 10.1007/s10238-021-00781-1
  4. Alismail H. Merging from traditional to potential novel breast cancer biomarkers. Journal of King Saud University-Science. 2024; 103551. DOI: 10.1016/j.jksus.2024.103551
  5. Donthu N, Kumar S, Mukherjee D, Pandey N, Lim, WM. How to conduct a bibliometric analysis: An overview and guidelines. J Bus Res. 2021;133:285-96. DOI: 10.1016/j.jbusres.2021.04.070
  6. Chakraborty S, Sharma G, Karmakar S, Banerjee S. Multi-OMICS approaches in cancer biology: New era in cancer therapy. Biochim Biophys Acta Mol Basis Dis. 2024;1870(5). DOI: 10.1016/j. bbadis.2024.167120
  7. Yıllık PA Bibliometric Analysis of Wearable Health Technology Research. Bilge International Journal of Science and Technology Research. 2023;7(2):187-97. DOI: 10.30516/bilgesci.1358090
  8. Aria M, Cuccurullo C. Bibliometrix: An R-tool for comprehensive science mapping analysis. J Informetr. 2017;11(4):959-75. DOI: 10.1016/j.joi.2017.08.007
  9. Jain J, Walia N, Singh S, et al. Mapping the field of behavioural biases: a literature review using bibliometric analysis. Management Review Quarterly 2022;72(3):823-55. DOI: 10.1007/s11301-021-00215-y
  10. Gu Y, Han F, Xue M, Wang M, Huang Y. Breast cancer screening and early diagnosis in China: a systematic review and meta-analysis on 10.72 million women. BMC Womens Health. 2024;24(1). DOI: 10.1186/s12905-024-02924-4
  11. Obeagu EI, Obeagu GU. Breast cancer: A review of risk factors and diagnosis. Medicine. 2024;103(3):E36905. DOI: 10.1097/MD.0000000000036905
  12. Wadasadawala T, Mohanty SK, Sen S, Kanala TS, Maiti S, Puchali N, et al. Out-of-pocket payment and financial risk protection for breast cancer treatment: a prospective study from India. The Lancet Regional Health - Southeast Asia. 2024;24. DOI: 10.1016/j.lansea.2023.100346
  13. Liang X, Vacher S, Boulai A, Bernard V, Baulande S, Bohec M, et al. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer. Breast Cancer Research. 2018;20(1). DOI: 10.1186/s13058-018-1007-x
  14. Corti G, Buchet R, Magrini A, Ciancaglini P, Mebarek S, Bottini M. The surface proteomic profile of serum extracellular vesicles as a diagnostic and prognostic tool in breast cancer., Current Opinion in Physiology. 2024; 100734. DOI: 10.1016/j.cophys.2023.100734
  15. Patel SA, Hassan MK, Naik M, Mohapatra N, Balan P, Korrapati PS, et al. EEF1A2 promotes HIF1A mediated breast cancer angiogenesis in normoxia and participates in a positive feedback loop with HIF1A in hypoxia. Br J Cancer. 2024;130(2):184-200. DOI: 10.1038/s41416-023-02509-2
  16. Shi, Y, Guo Z, Wang Q, Deng H. Prognostic value of tumor-infiltrating lymphocyte subtypes and microorganisms in triple-negative breast cancer. J Cancer Res Ther 2024;20(7):1983-90. DOI: 10.4103/jcrt.jcrt_41_24
  17. Howard FM, Olopade OI. Epidemiology of triple-negative breast cancer: a review. The Cancer Journal. 2021; 27(1):8-16. DOI: 10.1097/PPO.0000000000000500
  18. Yoon J, Oh DY. HER2-targeted therapies beyond breast cancer - an update. Vol. 21, Nature Reviews Clinical Oncology. Springer Nature. 2024; 675-700. DOI: 10.1038/s41571-024-00924-9
  19. Herath A. Multimodal Contrastive Clustering: Deep Unsupervised Learning Approach for Cancer Subtype Discovery with Multi-omics Data. Master’s thesis, University of Windsor 2024. DOI: 10.1016/j.procs.2024.09.488
  20. Singh D, Assaraf YG, Gacche RN. Long non-coding RNA mediated drug resistance in breast cancer. Drug Resistance Updates. 2022;63. DOI: 10.1016/j.drup.2022.100851
  21. Darbandi MR, Darbandi M, Darbandi S, Bado I, Hadizadeh M, Khorshid HRK. Artificial intelligence breakthroughs in pioneering early diagnosis and precision treatment of breast cancer: A multimethod study. Eur J Cancer 2024; 114227. DOI: 10.1016/j.ejca.2024.114227
DOI: https://doi.org/10.2478/rrlm-2025-0025 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624
Language: English
Page range: 251 - 258
Submitted on: Jul 22, 2025
|
Accepted on: Sep 13, 2025
|
Published on: Nov 6, 2025
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2025 Gamze Demirel, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution 4.0 License.